Skin Cancer Clinical Trial
— TISMISOfficial title:
Do Patients Undergoing Dermatologic Surgery Prefer the Use of Traditional Curved Iris Scissors or the Wuennenberg Modified Curved Iris Scissors?
NCT number | NCT04413383 |
Other study ID # | 2023744 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 21, 2020 |
Est. completion date | July 14, 2021 |
Verified date | August 2021 |
Source | University of Missouri-Columbia |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Every year thousands of dermatologic surgery procedures are performed at the University of Missouri Department of Dermatology, including Mohs Micrographic Surgery (MMS), Excisions, and biopsies. Surgery is known to cause anxiety for patients and with these procedures performed under local anesthetic on awake patients', the sights, sounds, and smells experienced during the procedure can lead to an increase in their anxiety or affect their overall perception of the experience. From performing and assisting with dermatologic surgery the noise associated with the use of the traditional curved Iris scissors provokes an increase in patient awareness to the procedure resulting in increased anxiety, triggering of the vasovagal response, and expressions of annoyance by the patient. However, the modified curved Iris scissors make almost no noise. The Investigators hypothesize that if patients were given the comparative experience of both types of curved Iris scissors during dermatologic surgery, then they will choose the modified curved Iris scissors because the lack of noise will be perceived as more pleasant experience. Our objective is to perform a prospective, single blinded, randomized controlled trial to determine how the noise of traditional curved Iris scissors vs the silent Wuennenberg modified curved Iris scissors affects patients during dermatologic surgery.
Status | Completed |
Enrollment | 147 |
Est. completion date | July 14, 2021 |
Est. primary completion date | July 14, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult (18 years or older) - non-pregnant - patients being treated with Mohs micrographic surgery or excision on the head and neck Exclusion Criteria: - Patients not meeting above inclusion criteria will be excluded. |
Country | Name | City | State |
---|---|---|---|
United States | UPMB | Columbia | Missouri |
Lead Sponsor | Collaborator |
---|---|
University of Missouri-Columbia |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Extent that patient notices curved Iris scissors | Questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient notices the use of the curved iris scissors. | 3 to 8 hours (length of the patients Mohs Surgery) | |
Primary | Extent that patient is bothered by the curved Iris scissors | Questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient is bothered by the curved iris scissors. | 3 to 8 hours (length of the patients Mohs Surgery) | |
Primary | Patients Preference of curved Iris scissor | Patient is asked during the procedure if they prefer "1," surgeon uses the traditional curved Iris scissors, or "2" and the surgeon uses the Wuennenberg modified curved Iris scissors. The patient indicates their preference by responding "1 or 2." After the procedure the patient completes a questionnaire with an ordinal scale from 1 to 10 to assess the extent that patient notices and is bothered by the curved iris scissors. | 3 to 8 hours (length of the patients Mohs Surgery) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT03740815 -
Feasibility of Serratus Plane Block Associated With Sedation in Axillary Dissection
|
N/A | |
Recruiting |
NCT05779423 -
Cryoablation+Ipilimumab+Nivolumab in Melanoma
|
Phase 2 | |
Terminated |
NCT01468818 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01820234 -
Evaluation of Store-and-Forward Teledermatology Versus a Face-to-Face Assessment During a Skin Cancer Screening Event
|
N/A | |
Completed |
NCT00535769 -
Evaluation of Adherence to Topical Agents: Applying Communication Technology to Improve Sunscreen Use
|
Phase 0 | |
Completed |
NCT00526032 -
Melanoma Detection by Oblique-Incidence Optical Spectroscopy
|
N/A | |
Completed |
NCT00588341 -
Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection
|
Phase 2 | |
Active, not recruiting |
NCT01447199 -
The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC)
|
||
Enrolling by invitation |
NCT04758988 -
AI Augmented Training for Skin Specialists
|
N/A | |
Not yet recruiting |
NCT04534868 -
Patient Acceptance And Satisfaction of Teledermoscopy In General Practice In a Belgian Rural Area
|
N/A | |
Recruiting |
NCT04138342 -
Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer
|
Phase 1 | |
Completed |
NCT03673917 -
Cosmetology Students and Skin Cancer
|
N/A | |
Recruiting |
NCT04341064 -
Sun-safe Habits Intervention and Education
|
Phase 3 | |
Completed |
NCT04206995 -
Cancer Sensing: Evaluation of Odour Sampling Techniques
|
||
Recruiting |
NCT05574101 -
A Study of Radiation Therapy and Cemiplimab for People With Skin Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05860881 -
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
|
Phase 3 | |
Completed |
NCT05146622 -
Virtual Sun Safe Workplaces Ph I
|
||
Recruiting |
NCT05068310 -
Applicability of a Cellular Resolution Full-field OCT Image System for Pigmented and Non-pigmented Skin Tumors
|
||
Recruiting |
NCT03889899 -
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
|
N/A |